Clinical trials: Doxorubicin Induced Cardiomyopathy
Doxorubicin Induced Cardiomyopathy
Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity
This study aims at evaluating the role of Atorvastatin in prevention of Anthracycline induced cardiotoxicity
- Trial name
- NCT05792293
- Testing
- Atorvastatin 40 Mg Oral Tablet
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Breast Cancer, Doxorubicin Induced Cardiomyopathy
99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer
This was a single center, proof-of-concept (PoC), Phase II study. Patients with histologically confirmed early stage (Stage I, II or III) HER-2 negative breast cancer and scheduled to receive doxorubicin-based (neo)adjuvant…
- Trial name
- NCT02677714
- Testing
- 99mTc-rhAnnexin V-128
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Advanced Accelerator Applications
Breast Cancer, Doxorubicin Induced Cardiomyopathy
Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
This study aims to evaluate the efficacy and safety of telmisartan as a cardioprotective agent in patients receiving doxorubicin-based chemotherapy, with the goal of reducing treatment-associated cardiotoxicity, optimizing…
- Trial name
- NCT07370506
- Testing
- Telmisartan, Doxorubicin (DOX)
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Tanta University
Cardiotoxicity, Osteosarcoma
Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR
using a contrast-enhanced (CE) cardiac magnetic resonance imaging(CMR) which included the measurement of T1 mapping, T2 mapping, T2* mapping and late gadolinium enhancement(LGE) sequences, as well as LVEF and extracellular…
- Conditions
- Cardiotoxicity, Osteosarcoma, Myocardial Injury, Chemotherapy Induced Systolic Dysfunction
- Trial name
- NCT04461223
- Testing
- contrast-enhanced cardiac magnetic resonance imaging(MAGNETOM Aera 1.5T)
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Cancer, Heart Failure
A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients
Purpose：1. Preliminary evaluation of the preventive effect of DH001 on doxorubicin-induced cardiotoxicity in cancer patients 2.To explore appropriate dosages to provide basis for dosages in subsequent confirmatory studies 3.To…
- Conditions
- Cancer, Heart Failure, Arrhythmia, Doxorubicin Induced Cardiomyopathy
- Trial name
- NCT06092606
- Testing
- Trial group: DH001 low-dose group, Trial group: DH001 high-dose group
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Monyan Pharmaceutical (Shanghai) Co., Ltd.
Cancer
Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin
Doxorubicin induced cardiomyopathy is the most common and serious side effect associated with doxorubicin treatment in cancer patients receiving doxorubicin.
- Trial name
- NCT06103279
- Testing
- Empagliflozin 10 MG
- Volunteers
- 40 people
- Sponsor
- Ain Shams University
Breast Cancer, Doxorubicin Induced Cardiomyopathy
The Potential Cardioprotective Effect of Addition of Atorvastatin in Breast Cancer Patients
the study aims to evaluate the cardioprotective effect of atorvastatin in breast cancer female patients treated with doxorubicin based chemotherapy
- Trial name
- NCT07668076
- Testing
- Atorvastatin
- Where
- Egypt
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Damanhour University
Doxorubicin Adverse Reaction, Cardiomyopathies, Secondary
The Role of suPAR Biomarker in Blood Samples of Breast Cancer Patients During and Post Doxorubicin Chemotherapy: Causative vs. Predictor
This study looks to find a causative or predictive aspect of the suPAR biomarker for heart failure in breast cancer patients receiving Doxorubicin drug chemo regimen.
- Conditions
- Doxorubicin Adverse Reaction, Cardiomyopathies, Secondary, Breast Cancer
- Trial name
- NCT03505164
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Rush University Medical Center
Doxorubicin Induced Cardiomyopathy, Chemotherapeutic Toxicity
Mitochondrial dysfUnction: a Key Player in Doxorubicin-induced Skeletal and Cardiac muscLE Damage
The goal of this observational study is to demonstrate the ability of using non-invasive Phosphorus (31P) Magnetic Resonance Spectroscopy (MRS) to monitor changes of in-vivo markers of mitochondrial function in skeletal and…
- Conditions
- Doxorubicin Induced Cardiomyopathy, Chemotherapeutic Toxicity, Anthracyclines
- Trial name
- MUSCLE (NCT05731375)
- Testing
- 31-MRS at 7 Tesla (T)
- Where
- 4 sites in Netherlands
- Volunteers
- 12 people
- Sponsor
- UMC Utrecht
Cardiotoxicity, Risk Factor, Cardiovascular
Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
Investigators will evaluate the safety, tolerability, and feasibility of a risk-guided cardioprotective treatment strategy with carvedilol, as compared to usual care, in breast cancer patients undergoing treatment with…
- Conditions
- Cardiotoxicity, Risk Factor, Cardiovascular, Toxicity Due to Chemotherapy, Breast Cancer
- Trial name
- CCTGuide Pilot (NCT04023110)
- Testing
- Carvedilol
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer Female, Doxorubicin Induced Cardiomyopathy
Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients
Twenty-seven breast cancer women without heart failure, underwent CMR imaging (3T-Achieva, Philips) before and 3 times serially after 4-cycles of adjuvant DOX (60mg/m2).
- Trial name
- NCT03000036
- Testing
- Doxorubicin, Achieva, Philips Medical Systems (3T magnet), Gadoterate Meglumine
- Where
- Brazil
- Volunteers
- 27 people
- Sponsor
- University of Campinas, Brazil
Doxorubicin Induced Cardiomyopathy, Breast Cancer
Prevention Using Exercise Rehabilitation to Offset Cardiac Toxicities Induced Via Chemotherapy
The purpose of this study is to identify patients at risk for future heart failure using novel markers of early cardiac damage and determine if exercise training can improve these emerging markers as well as overall fitness and…
- Conditions
- Doxorubicin Induced Cardiomyopathy, Breast Cancer, Gastric Cancer, Leukemia
- Trial name
- HF-PROACTIVE (NCT02796365)
- Testing
- Exercise
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Henry Ford Health System
Doxorubicin Induced Cardiomyopathy, Breast Cancer
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity
This is a randomized controlled clinical trial that aims to evaluate the safety and efficacy of Dapagliflozin as a cardioprotective in doxorubicin-induced cardiotoxicity in breast cancer patients.
- Trial name
- NCT06427226
- Testing
- Dapagliflozin 10mg Tab
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Tanta University
Breast Cancer
Pilot Study to Evaluate the Prevention and Safety of Doxorubicin-induced Cardiomyopathy Using Extracorporeal Shock Waves
Until now, patients receiving doxorubicin chemotherapy should use only the cumulative dose related to known cardiotoxicity, or if cardiotoxicity occurs below the known cumulative dose, use of doxorubicin as chemotherapy should be…
- Trial name
- NCT05584163
- Testing
- Extracorporeal shock waves
- Where
- South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ewha Womans University Mokdong Hospital
Anthracycline Induced Cardiotoxicity
Late Anthracycline Induced Cardiotoxicity- Childhood Cancer Survivors
Anthracyclines treat up to 60% of childhood malignancies with remarkable improvements survival rates. Unfortunately anthracyclines are associated with an increased cardiomyopathy risk.
- Trial name
- NCT04852965
- Where
- United Kingdom
- Volunteers
- 103 people
- Sponsor
- Queen's University, Belfast